Myriad Genetics published details of its myVision program Myriad Genetics announced that it has published details of its myVision Myriad Variant Classification Program in the journal Clinical Genetics. myVision is the most advanced variant classification program available to determine whether a patient's genetic variant is benign or deleterious. myVision employs a number of robust scientific methods and is backed by Myriad's 20 years of clinical research and testing in more than one million patients. "Patients who receive a genetic test that identifies a variant of uncertain significance, or VUS, do not know if their mutation is benign or deleterious and associated with hereditary cancer risk. This lack of clarity is emotionally difficult and confusing for patients who are making medical decisions and may translate into substantial downstream healthcare costs," said the company.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Myriad Genetics advises prior BRACAnalysis news release be disregarded Myriad Genetics advised that readers should disregard the news release, "Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis" issued April 7 by the company over GlobeNewswire.